Consistent Results Observed With Topical Roflumilast in Second Atopic Dermatitis Trial
The INTEGUMENT-2 trial included patients 6 years of age and older with mild to moderate atopic dermatitis involving at least 3% body surface area.
The INTEGUMENT-2 trial included patients 6 years of age and older with mild to moderate atopic dermatitis involving at least 3% body surface area.
The BE HEARD I and BE HEARD II studies included more than 1000 adults with moderate to severe hidradenitis suppurativa.
The trial met its primary endpoint with a significantly larger proportion of delgocitnib-treated patients achieving treatment success.
The approval was based on data from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials in adults with moderate to severe plaque psoriasis.
B-VEC is an investigational topical gene therapy designed to deliver 2 copies of the COL7A1 gene when applied directly to DEB wounds.
The Companies are in violation of the FD&C Act, as these products are being marketed with unauthorized claims to remove lesions, including moles and skin tags.
NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes.
CTP-543 is an investigational oral selective inhibitor of JAK1 and JAK2.
The approval was based on data from the two phase 3 trials that included patients aged 12 years and older with mild to severe plaque psoriasis.
The approval was based on data from two phase 3 studies, which included patients 12 years of age and older with nonsegmental vitiligo who had depigmented areas.